Announcements Trials
Browse Landscape

Phase

Phase 1 11Phase NA 9Phase 2 8Phase 1/2 3Phase 3 2Phase 4 1Phase 2/3 1

Status

Completed 329Recruiting 167Terminated 142Active not recruiting 80Unknown 78Not yet recruiting 31Withdrawn 27Suspended 3Enrolling by invitation 2

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 14Other hematologic neoplasm 7Lymphoid 6Dermatologic 5Tumor-Agnostic 4Thoracic 4CNS 4Other solid neoplasm 3Myeloid 3Genitourinary 3Breast 3Sarcoma 2Plasma cell 2Gynecologic 2NET 1Endocrine 1

Conditions

Prostatic Neoplasms 2Vulvar Neoplasms 1Sarcoma 1Ovarian Neoplasms 1Neuroendocrine Tumors 1Melanoma 1Hypotension 1Gallbladder Neoplasms 1Carcinoma, Renal Cell 1Carcinoma, Neuroendocrine 1Breast Neoplasms 1Bile Duct Neoplasms 1

Interventions

tivozanib 1imisopasem manganese 1atezolizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 1/2 × Suspended × Genitourinary × Clear all
NCT05000294 2026-02-18

Atezolizumab Plus Tivozanib in Immunologically Cold Tumor Types

University of Florida

Phase 1/2 Suspended
29 enrolled
BreastEndocrineGastrointestinalGenitourinaryGynecologicNETSarcoma

Bile Duct Neoplasms, Breast Neoplasms, Gallbladder Neoplasms, Ovarian Neoplasms, Prostatic Neoplasms, Sarcoma, Vulvar Neoplasms, Carcinoma, Neuroendocrine, Neuroendocrine Tumors

NCT06643494 2025-03-11

Elimination of Prostate Cancer Treatment Side Effects Using a Nutraceutical

Optimal Health Research

Phase 1/2 Suspended
100 enrolled
Genitourinary

Prostatic Neoplasms

NCT00033956 2005-06-24

Evaluation of M40403 for the Prevention of Dose Limiting Toxicities of High Dose IL-2

MetaPhore Pharmaceuticals

Phase 1/2 Suspended
48 enrolled
DermatologicGenitourinary

Carcinoma, Renal Cell, Hypotension, Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡